The European Medicines Agency (EMA) has updated its guidance on shortage prevention plans for medicines marketed in the EU, ahead of new legal requirements expected by mid-2027. The update matters because marketing authorisation holders (MAHs) must identify supply-chain vulnerabilities, classify
